Gamida up as FDA grants priority review to blood cancer therapy

Gamida Cell

01/08/2022 12:42

** Shares of Israel-based biopharma co Gamida Cell  GMDA.O 
rise ~12.6% to $1.88 premarket
    ** U.S. FDA grants priority review to omidubicel, Gamida's
experimental cell therapy for patients with cancers in need of
stem cell transplant  urn:newsml:reuters.com:*:nASA03IHO
    ** FDA has given target date of Jan. 30, 2023 for its
decision
    ** Health agency is not planning an advisory committee
meeting as part of review
    ** Up to last close, stock fell 37.4% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))